z-logo
Premium
Haemoconcentration of residual cardiopulmonary bypass blood using Hemosep ® : a randomised controlled trial
Author(s) -
Hogan M.,
Needham A.,
Ortmann E.,
Bottrill F.,
Collier T. J.,
Besser M. W.,
Klein A. A.
Publication year - 2015
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1111/anae.13019
Subject(s) - autotransfusion , cardiopulmonary bypass , medicine , anesthesia , dose , cardiac surgery , blood transfusion , surgery , cardiology
Summary Cardiac surgery and cardiopulmonary bypass are associated with haemodilution, activation of haemostasis and blood transfusion. We undertook a randomised controlled trial that included 53 patients in order to compare autotransfusion of residual cardiopulmonary bypass blood with residual blood concentrated using the novel Hemosep ® device. There was no difference in patients' mean ( SD ) haemoglobin concentration after autotransfusion of unprocessed blood compared with Hemosep; 103.5 (10.2) g.l −1 vs 106.2 (12.4) g.l −1 , respectively, p = 0.40. The mean ( SD ) change in haemoglobin concentration after autotransfusion was 5.9 (5.3) g.l −1 in the control group compared with 4.9 (6.3) g.l −1 in the Hemosep group, p = 0.545. Adjusted for baseline haemoglobin concentrations, the estimated mean (95% CI) difference in change in haemoglobin concentration (control vs Hemosep) was 0.57 (−2.65 to 3.79) g.l −1 , p = 0.72. This was despite Hemosep's reducing the weight of the blood from a mean ( SD ) of 778.7 (243.0) g to 607.3 (248.2) g, p < 0.001. The haemoglobin concentration in the processed blood increased from a mean ( SD ) of 87.0 (15.1) g.l −1 to 103.7 (17.4) g.l −1 , p < 0.001. We conclude that Hemosep is capable of haemoconcentration when employed to process residual cardiopulmonary bypass blood, but that this is insufficient to increase patient haemoglobin.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here